A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Objective: To evaluate the cost-effectiveness of brentuximab vedotin in patients with R/R sALCL from a UK NHS perspective. Methods: A partitioned survival model used clinical outcomes for brentuximab vedotin from the pivotal phase-2 single-arm trial of brentuximab vedotin in 58 patients with R/R sAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Hux, Margaret, Zou, Denise, Ma, Esprit, Sajosi, Peter, Engstrom, Andreas, Selby, Ross, Benson, Eugene, Briggs, Andrew, Bonthapally, Vijayveer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471416/
https://www.ncbi.nlm.nih.gov/pubmed/37661948
http://dx.doi.org/10.36469/9820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471416/
https://www.ncbi.nlm.nih.gov/pubmed/37661948
http://dx.doi.org/10.36469/9820

Ejemplares similares